Purpose: According to the IMvigor130 trial, adding atezolizumab to platinum-based
chemotherapy was effective in the treatment of metastatic urothelial cancer (mUC). Based on …

Abstract Introduction The IMvigor130 trial found that atezolizumab plus platinum-based
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …

Purpose: To evaluate the cost–effectiveness of atezolizumab plus chemotherapy as first-line
treatment for metastatic urothelial cancer (mUC). Materials & methods: A Markov model was …

Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …

Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …

Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …

Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …

Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally …

461 Background: Atezolizumab is approved for use in advanced urothelial cancer in second
line setting after platinum based chemotherapy. We conducted a retrospective study to …

Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …